CN Patent

CN117677398A — 用于癌的治疗和/或预防的药品

Assigned to Toray Industries Inc · Expires 2024-03-08 · 2y expired

What this patent protects

本发明涉及用于癌的治疗和/或预防的药品，其特征在于，一起包含或各自分开地组合包含：与CAPRIN‑1蛋白质具有免疫反应性的抗体或其片段、和MAPK通路抑制剂。

USPTO Abstract

本发明涉及用于癌的治疗和/或预防的药品，其特征在于，一起包含或各自分开地组合包含：与CAPRIN‑1蛋白质具有免疫反应性的抗体或其片段、和MAPK通路抑制剂。

Drugs covered by this patent

Krazati (ADAGRASIB) · Bristol-Myers Squibb

Patent Metadata

Patent number: CN117677398A
Jurisdiction: CN
Classification: —
Expires: 2024-03-08
Drug substance claim: No
Drug product claim: No
Assignee: Toray Industries Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.